MedTrace Logo

Vision Response to Dopamine Replacement

NCT01663935 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-06-11

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate and document physiologic and functional changes in visual performance and retinal function of patients diagnosed with albinism (a dopamine deficiency state) following a trial of oral Levodopa/carbidopa treatment.

Conditions

  • Albinism
  • Oculocutaneous Albinism

Interventions

DRUG

Levodopa/carbidopa

This study will have an intent to treat goal. Anyone that fits the inclusion criteria for the study will be entered and receive study drug.

Sponsors & Collaborators

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Michael C Struck, MD · University of Wisconsin, Madison

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-17
Primary Completion
2018-04-12
Completion
2018-04-12

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01663935 on ClinicalTrials.gov